|Bid||20.53 x 1200|
|Ask||20.54 x 800|
|Day's range||20.09 - 21.42|
|52-week range||17.51 - 60.04|
|Beta (3Y monthly)||0.75|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The CHMP recommends Aerie's (AERI) marketing application for Rhokiinsa to reduce elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
As the US$994m market cap Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released another year of negative earnings...
Aerie (AERI) delivered earnings and revenue surprises of 8.05% and 8.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Aerie (AERI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anyone researching Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) might want to consider the historical volatility of the...
Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.
Aerie (AERI) delivered earnings and revenue surprises of 14.29% and -14.27%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The North Carolina, North Carolina-based company said it had a loss of $1.06 per share. Losses, adjusted for non-recurring costs, came to 78 cents per share. The results exceeded Wall Street expectations. ...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak perf...
Aerie (AERI) begins dosing in a phase II study on netarsudil ophthalmic solution in Japan for curbing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Shares Up.
Aerie (AERI) gets FDA approval for Rocklatan to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension and announces its 2019 revenue and cash burn outlook.
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But when you pick aRead More...